1Ellerhorst J A, Sella A, Amato R J, et al. Phase Ⅱ trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer, 1997, 80: 2128-2132.
2Ishikawa T, Sekiguchi F, Fukase Y, et al. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine ( capecitabine ). Biol Pharm Bull, 1998, 21: 713-717.
3Wenzel C, Schmidinger M P, Locker G J, et al. Oral chemotherapy with capecitabineXeloda) in the treatment of metastatic renal cancer failing immunotherapy. Proc Am Soc Clin Oncol, 2000, 19: 368a-368a.
4Oevermann K, Buer J, Hoffmann R, et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J of Cancer,2000,83: 583-587.
同被引文献10
1Therasse P, Arbuck SC, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [J]. J Nail Cancer Inst,2000.92(3):205-216.
2Nagalakshmi ML, Rasele A, Zurawski S, et al. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells [J]. Int Immunopharmacol,2004,4(5):679-691.
3Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues [J]. Immunity,2004,21(2):241-254.
4de Vita VTJ,Hellman S,Rosenberg SA,et al.Cancer principles and practice of oncology[M].6th ed.Philadelphia:Lippincott Williams & Wilkins,2001:1140-1168.
5Therasse P,Arbuck SC,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors[J].J Nafl Cancer Inst,2000,92(3):205-216.
6Lopez-Beltran A,Montironi R,Kirkali Z,et al.2004 WHO classification of the renal tumors of the adults[J].European Urology,2006,49:798-805.
8Padrik P,Leppik K,Arak A.A phase Ⅱ study of combination therapy with capecitabine and interferon alfa2A in patients with metastatic renal cell carcinoma[J].Proc Am Soc Clin Oncol,2003,22:1626.
9Wenzel C,Schmidinger MP,Locker GJ,et al.Oral chemotherapy with capecitabine(Xeloda) in the treatment of metastatic renal cancer failing immunotherapy[J].Proc Am Soc Clin Oncol,2000,19:368a.
